February 27, 2021
1 min read
Source / information
Published by:
Disclosure:
Sun reports it has received grants from the NIH. In the study you will find all relevant financial information from all other authors.
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact [email protected].
Back to Healio
Real data reported in clinical infectious diseases showed that the recombinant zoster vaccine was more than 85% effective at preventing herpes zoster.
The recombinant herpes zoster (RZV) vaccine has previously been shown to be more protective and less expensive than live vaccine or no vaccine. Another study showed that herpes zoster-related pain was reduced.
Source: Sun Y et al. Clin Infect Dis. 2021; doi: 10.1093 / cid / ciab121.
“Understanding the effectiveness of RZV in practice outside of clinical trial settings is critical given the differences between clinical trial settings and general practice.” Yuwei Sun, MS, An analyst at the University of California, the Francis I. Proctor Foundation for Ophthalmic Research in San Francisco, and colleagues wrote. “The clinical trials had standardized protocols for vaccine storage, administration and herpes zoster diagnosis. In general practice, patients often have more comorbidities. “
Sun and colleagues conducted a retrospective cohort study of 4.7 million immunocompromised individuals of vaccine age using an unidentified harm database. A total of 173,745 adults received two doses of RZV.
The results showed that the herpes zoster incidence rate for those who received the vaccine was 258.8 cases per 100,000 person-years (95% CI, 230-289.4) and for those who were not vaccinated it was 893.1 per 100,000 person-years (95% CI) % CI, 886.2-900). Efficacy was 85.5% (95% CI, 83.5% -87.3%) overall, 86.8% (95% CI, 84.6% -88.7%) in patients over the age of 50 up to 79 years and 80.3% (95% CI, 75.1%) calculated% -84.3%) in patients over 80 years. In addition, efficacy was 84.8% (95% CI, 75.3% -90.7%) in patients who had a live herpes zoster vaccine within 5 years of enrollment in the study.
The authors noted that the limitations of the study included limited data for participants ages 50 to 59 and the inability to assess weight loss due to the analysis’s short follow-up.
“It will be of critical importance to identify potential barriers to future uptake of recombinant herpes zoster vaccines,” the authors write. “More research and health efforts are needed to identify and remove potential barriers to herpes zoster vaccination in order to protect more people from this common disease.”
perspective
Back to top
William Schaffner, MD
As you move from a clinical trial to the real world, you wonder whether the results obtained in the clinical trial – in this case excellent results – are comparable to a real world environment. Clinical trials are a very sophisticated environment in which certain patients are excluded from participation. But in the real world, everyone gets the vaccine.
It is very comforting to see that this real-world data fully supports the excellent efficacy results achieved in the clinical trials. You should definitely encourage anyone 50 or older to get the RZV.
William Schaffner, MD
Member of the editorial team for infectious diseases
Medical Director of the National Infectious Diseases Foundation
Professor of Preventive Medicine and Infectious Diseases
Vanderbilt University Medical Center
Disclosure: Schaffner does not report any relevant financial information.
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact [email protected].
Back to Healio
